Nevanac Related Published Studies
Well-designed clinical trials related to Nevanac (Nepafenac Ophthalmic)
Effects of topical nepafenac on corneal epithelial healing time and postoperative pain after PRK: a bilateral, prospective, randomized, masked trial. [2008.04]
Analgesic and anti-inflammatory effectiveness of nepafenac 0.1% for cataract surgery. [2007.12]
Ketorolac tromethamine LS 0.4% versus nepafenac 0.1% in patients having cataract surgery. Prospective randomized double-masked clinical trial. [2007.11]
In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac. [2007.09]
Prostaglandin E2 inhibition and aqueous concentration of ketorolac 0.4% (acular LS) and nepafenac 0.1% (nevanac) in patients undergoing phacoemulsification. [2007.07]
Nepafenac ophthalmic suspension 0.1% for the prevention and treatment of ocular inflammation associated with cataract surgery. [2007.01]
Comparison of the analgesic efficacy and safety of nepafenac ophthalmic suspension compared with diclofenac ophthalmic solution for ocular pain and photophobia after excimer laser surgery: a phase II, randomized, double-masked trial. [2006.04]
Well-designed clinical trials possibly related to Nevanac (Nepafenac Ophthalmic)
Effects of nonsteroidal ophthalmic drops on epithelial healing and pain in patients undergoing bilateral photorefractive keratectomy (PRK). [2007.11]
Other research related to Nevanac (Nepafenac Ophthalmic)
Impact of nepafenac 0.1% on macular thickness and postoperative visual acuity after cataract surgery in patients at low risk for cystoid macular oedema. [2009.02.20]
Inhibition of surgically induced miosis and prevention of postoperative macular edema with nepafenac. [2009]
Treatment of cystoid macular edema with the new-generation NSAID nepafenac 0.1%. [2009]
Nepafenac dosing frequency for ocular pain and inflammation associated with cataract surgery. [2008.12]
Topical nepafenac as an alternate treatment for cystoid macular edema in steroid responsive patients. [2008.11]
Effect of nepafenac sodium 0.1% on delayed corneal epithelial healing and haze after photorefractive keratectomy: retrospective comparative study. [2008.09]
Corneal melting after use of nepafenac in a patient with chronic cystoid macular edema after cataract surgery. [2008.03]
Cystoid and diabetic macular edema treated with nepafenac 0.1%. [2007.12]
Nepafenac-associated corneal melt. [2007.11]
Incidence of visually significant pseudophakic macular edema after uneventful phacoemulsification in patients treated with nepafenac. [2007.09]
Case of corneal melting associated with the use of topical nepafenac. [2007.09]
The use of a cyclooxygenase-2 inhibitor (Nepafenac) in an ocular and metastatic animal model of uveal melanoma. [2007.09]
Double-masked comparison of ketorolac tromethamine 0.4% versus nepafenac sodium 0.1% for postoperative healing rates and pain control in eyes undergoing surface ablation. [2007.07]
Double-masked study of the effects of nepafenac 0.1% and ketorolac 0.4% on corneal epithelial wound healing and pain after photorefractive keratectomy. [2007.07]
Topical administration of nepafenac inhibits diabetes-induced retinal microvascular disease and underlying abnormalities of retinal metabolism and physiology. [2007.02]
Ocular permeation and inhibition of retinal inflammation: an examination of data and expert opinion on the clinical utility of nepafenac. [2006.02]
Inflammation-mediated retinal edema in the rabbit is inhibited by topical nepafenac. [2003.10]
Topical nepafenac inhibits ocular neovascularization. [2003.01]
Other possibly related research studies
Effects of topical anti-inflammatory agents in a botulinum toxin B-induced mouse model of keratoconjunctivitis sicca. [2007.02]
Pharmacokinetics of topical ocular drug delivery: potential uses for the treatment of diseases of the posterior segment and beyond. [2003.06]
|
